ArticleEndocrine2026
Alterations in gut microbiota and metabolic profiling are associated with papillary thyroid cancer and BRAF
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEmerging evidence indicates that gut microbial dysbiosis contributes to cancer development through metabolic regulation. The gut microbial and metabolic characteristics of papillary thyroid cancer (PTC) remain incompletely characterized, and the role of microbial dysbiosis in PTC tumorigenesis is not well understood.
methodsThis study recruited 70 PTC patients and 70 healthy controls (HCs) and performed 16S rRNA sequencing and LC-MS/MS metabolomic analysis of fecal samples.
resultsThe PTC group demonstrated significantly greater microbial diversity and richness compared to the HC group. Substantial differences in microbiota composition were also observed between the two groups. Analysis revealed 19 differentially expressed bacterial taxa in PTC patients relative to HCs, including enriched pathogens (Collinsella, Carnobacterium, and Moryella) and depleted protective bacteria (Lacticaseibacillus, Faecalibaculum, Coprobacter, Anaerotruncus, Leuconostoc, and Acetanaerobacterium). A random forest model with 10-fold cross-validation based on all bacteria detected was used and the prediction model performed best with a mean AUC of 0.769 when 21 features including differentially abundant genera Methyloprofundus, Collinsella, TM7a and Acetanaerobacterium were selected. Microbial co-occurrence network analysis demonstrated stronger correlations between bacterial taxa in PTC compared to HC. Metabolomic profiling identified 20 significantly differentially expressed metabolites in PTC, including elevated levels of ornithine and lysine. Further investigation revealed associations between tumor-associated microbes and metabolites involved in ornithine and lysine metabolic pathways, suggesting a potential mechanism through which gut microbiota may correlate with tumorigenesis. Finally, we conducted comparative analysis of microbial and metabolic profiles between BRAF mutation (BRAFmut) and BRAF wild-type (BRAFwt) patients. Integrative analysis indicated that BRAFmut-enriched Halomonas was negatively correlated with leucine and lysine, providing a plausible hypothesis for microbial-mediated mutagenic effects.
conclusionThis study elucidates the distinctive distribution and correlation patterns of gut metabolites and microbiota in PTC, offering valuable insights into the pathogenesis and progression of thyroid cancer.
Indexed as
Identifiers
42043696What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.